AVBP as reported
- Net Income
- −$164M
Net Income · +20% year on year · trailing twelve months to Q2 2026
- EPS
- −$3.62
EPS · −10.0% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$164M | +20% | Q2 2026 |
| EPS | −$3.62 | −10.0% | Q2 2026 |
| ROE | −48% | n/a | Q2 2026 |
| ROA | −45% | n/a | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
ArriVent BioPharma, Inc. (AVBP) - Net IncomeNet IncomeArriVent BioPharma, Inc. (AVBP)